Jefferies Group Lowers ThromboGenics Price Target to €33.00 (THR)
Research analysts at Jefferies Group decreased their target price on shares of ThromboGenics (EU:THR) from €36.00 ($50.00) to €33.00 ($45.83) in a report released on Tuesday, American Banking and Market News reports. The firm currently has a “buy” rating on the stock.
ThromboGenics (EU:THR) traded down 0.38% during mid-day trading on Tuesday, hitting $23.84. 134,854 shares of the company’s stock traded hands. ThromboGenics has a 1-year low of $17.99 and a 1-year high of $26.24. The stock’s 50-day moving average is $20.55 and its 200-day moving average is $20.60. The company has a market cap of $749.2 million and a price-to-earnings ratio of 56.17.
Thermon Group Holdings, Inc is a provider of engineered thermal solutions for process industries. The Company products include a range of electric heat tracing cables, steam tracing components, and tubing bundles, as well as instrument and control products, including self-regulating and power limiting heating cables, which automatically increase or decrease heat output as pipe temperature changes; mineral insulated (EU:THR), cable, which is a high performance heat tracing cable for generating high temperatures that is used in harsh environments; heat traced tube bundles for environmental gas sampling systems; heat transfer compounds and steam tracers for steam tracing solutions; control and monitoring systems for electric tracing of pipes, tanks, hoppers and instrument sampling systems, and turnkey solutions that provide customers with complete solutions for heat tracing, including design, optimization, installation and ongoing maintenance.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.